Takeda and Cognition Kit Present Results from Digital Wearable Technology Study in patients with Major Depressive Disorder (MDD) - Seite 2
Given the exploratory nature of these study findings, they will be hypothesis generating and will contribute to decision making for future clinical studies involving wearable technology.
About Major Depressive Disorder
According to the American Psychiatric Association (APA), authors of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-V), MDD is a combination of symptoms that affects how you feel, the way you think and how you act. In addition to depressed mood or sadness, MDD symptoms include loss of interest, changes in appetite or weight, insomnia or oversleeping, loss of energy, restlessness or having slowed speech and movements, feelings of worthlessness or guilt, difficulty thinking or making decisions and thoughts of suicide. MDD includes five or more of these symptoms with at least one core symptom of either depressed mood or loss of interest or pleasure.i
About Cognition Kit Limited
Cognition Kit is a software platform for mobile and wearable technology, designed to capture high frequency patient-centered outcomes. Cognition Kit takes research out of the lab and into daily life, enabling doctors, scientists and the public to better understand and manage brain health and enhance patient care. Cognition Kit is a joint venture between Cambridge Cognition and Ctrl Group.
www.cognitionkit.com
@CognitionKit
Lesen Sie auch
hello@cognitionkit.com
About Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceutical Company Limited is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into
life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty
cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Takeda's growth is being
fuelled by products, especially in oncology and gastroenterology, as well as its presence in emerging markets. More than 30,000 Takeda employees are committed to improving quality of life for
patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.